It was found that patients with high GS tended to have high MAFG-AS1 expression level (GS = 6: 1.29 ± 0.70, GS = 7: 1.58 ± 0.84, and GS ≥ 8: 1.84 ± 0.92, p < 0.001), and the significant difference was also observed in the pathological T stage category, lymph node metastasis category, and BCR status category (≤T2c: 1.52 ± 0.81, T3/T4: 1.75 ± 0.92, p = 0.005; lymph node metastasis-positive: 1.89 ± 0.99, lymph node metastasis-negative: 1.62 ± 0.87, p = 0.018; BCR-positive: 1.94 ± 0.91, BCR-negative: 1.58 ± 0.86, p < 0.001), as shown in Supplementary Table S8. Here, MAFG is linked to metastatic malignant neoplasm in the lymph nodes.